ISR - Earnings call transcript Q3 2019 | Perspective Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the IsoRay Third Quarter Fiscal 2019 Call. All lines have been placed in a listen-only mode and the floor will be open for your questions and comments following the presentation. [Operator Instructions]. At this time, it’s my pleasure to turn the floor over to Mr. Mark Levin. yours. is floor the Sir,

Mark Levin

Thank you, us XXXX you joining XX, and call Good for the afternoon XXXX. March today ended quarter the thank IsoRay for for quarter operator. fiscal earnings third

such they Act will I statements. When future Act statements will, expressions of Litigation the similar company’s forward-looking in within management as and XXXX. within events. started, get are statements of about meaning statements management call, assumptions management’s to information in as we take few well this the by Reform read statements forward-looking meaning Certain constitute minutes call conference anticipate, relate amended. Reform of These expectations its forward-looking of expect, XXXX, the company used encourage, made and on the a conference beliefs this the as the to identify based as forward-looking the words believe, Securities or Before Private currently Private current to available Litigation as Securities and

with susceptible or in whether to they company disclaims uncertainty are its and any such update statements from any information, new alter or changes, events otherwise. inherently obligation undertakes expressly forward-looking changes and the to, circumstances forecast, resulting and projection subsequent As obligation no to, or

on under Additional with filings the statement contained concerning call listed information XXXX. forward-looking Safe as in statements Commission. are May the company's X, Securities made the Harbor from Statements of heading today's is of and Exchange time-to-time Risk today, Factors and

will fiscal quarter will Executive Officer, Hunt, IsoRay's Chief Officer. the Chief today's And third Lori who Jonathan with IsoRay's Woods, results. We then Financial financial begin call discuss

Lori our over we institutional remarks, and now I will Following to turn investors. analysts the their questions will take from call Woods. prepared

Lori Woods

I updates afternoon, and I some financial Hunt, on provide quarter detailed earnings XXXX. will products review you, the results. and more then quarter for ended begin fiscal some Financial over as highlights third joining financial call strategic other IsoRay’s you who quarter’s launched then our results third the today initiatives. well from March the with will Chief conference for XXXX recently XX, call quarter will call thank Mark. for the as the us Good third ongoing XXXX Thank fiscal Jonathan a IsoRay’s give turn Officer, will developments and of to I

We are XX% third quarter double-digit and key the fiscal growth of this driver core of margin third revenue, versus our gross quarter of marks pleased revenue report sales year-ago to with XXXX another increased quarter over of again, brachytherapy growth profit. Once the This gross consecutive quarter was XXXX. growing eighth XX% IsoRay’s fiscal quarter. the record quarter revenue which of prostate

strategies continue the patients Cesium-XXX to see of increased adoption, proprietary awareness and drive treatment our We our in of isotope sales utilization cancer. prostate battling and marketing

as is driving as we are marketing on growth speak the and results our leadership such our product growing improved and efforts both quarter’s prostate encouraging patients. strategic have clinicians and within to market. This These to initiative brachytherapy and awareness media the the introductions complementary focus position

new develop to as customers. expand relationship existing opportunities resulting our customers with the in as payoff the seeing well are We further

including deliver further outcomes We respect measurably with improvement believe and part building We physicians, is It of this treatment and outreach. yielding healthcare patients in benefits pressure resolving serves treatment results. overall as effective is awareness payers market also growth and trajectory believe cost. that of life compared focused side experiencing increasingly considering effects sense business we the faster see driven our cost, for overall increased positioning the is healthcare resulting of patients to advantages, prostate our research Cesium-XXX’s in non-brachytherapy our messaging from to that our the brachytherapy consistent and quality when industry options by the to

expanding launched treated a radiation continue Blu up adjacent from increasing interest will which this and awareness helped opportunities We in coverage One was that in William we believe the expect story. effectiveness community. and resulting we Recall patients Build. our recent subsequently build for on about have of and prostate clinicians to build another current also asking products key of the the new limited more by are and Health is and David as anticipation the AnMed capacity of tweaks launch Cesium-XXX proprietary we communications sign to sense treatment media result, interest theirs of that from strategic Center availability has of of saw we adjustments broader and Dr. of we an at minor a It first introduction to the initiative. continue by interest general the by Cancer is at in is to portion product our date oncology date. Tomlinson as in the Build, pick to generate a brachytherapy the been markets feedback Blu others served media in Hollings benefit from commercial in always particular Further, invaluable receive continues extensive to yet Dr. lot Marshall making isotope. launch patients for seeking by particularly from our product As that has well doctors

our of in our market prostate opportunity may increases serves as belief the recall market. into we the that as discussed it Blu customization our entrée You that brachytherapy Build segment

that no where have Our presence medical us previously. segment allows essentially to we enter had technology advancement

expands continue estimate $XX that domestic Blu prostate Build by million We million. opportunity $XXX cancer to approximately to our

growth IsoRay’s in was Texas Oncology training a leadership with prestigious Another announcement. that example market collaboration brachytherapy announcement group. you of read IsoRay’s I’m hopeful positioning industry of strategic focus the recent our fuel and on to

a It leading body.” collaboration perspective press the is section ultimately to builds the the more it message generation and difference I that of educate Dr. brachytherapy throughout states, to I utilizing treatment Cesium-XXX of also will train believe positioning Cesium-XXX mission brachytherapists brachytherapy. Texas is can results. of It Cesium-XXX prostate to physicians our other the will will believe commitment and Dr. Dr. Taylor and and benefits at and to deep in who significant prostate while key make quote not of physicians, Web methodology. brachytherapy We real-time program serves to radiation uses exclusively was of available. cancers brachytherapy two like seasoned brachytherapy the that You Dr. collaboration using will training with program cancer expand observations, Cesium-XXX the survivor our only isotope Oncology. prostates, is our a on unique the which leaders. posted cancer treatment important and Taylor “In procedure also best believe release physics planning treated access see The a now and prostate develop unique of will by he adoption giving include on site. of research to industry also a case fact, that represents The option brachytherapy but we have train this on is demonstrate and in artificial which director more the the note as the the Key in on benefits Taylor, sees Cesium-XXX next himself patients leader influential Taylor, of Bernard of oncology practice voices

physicist how XX This commonly brachytherapy, palladium. host Health periodic superior Atef Cesium-XXX Web to webinar on the switch which of Maryland. mono presentation of continue and benefits in Taylor we isotopes switching Omari, forward webinar Additionally, The candid gave future a he by replay medical Bon key make compelling on our seamlessly isotopes of such of the was look Dr. Systems first and Dr. and the to at Dr. on from training both in on over will therapy other as on site co-hosted Cesium-XXX. was combination brachytherapy in as focused isotopes webinars and Taylor other Secours available topics and and did to April to within webinars first other the Cesium-XXX is used held iodine XXXX. and

year’s unique look build Cesium-XXX efforts be we leadership will to furthering we isotope. IsoRay’s in for our brachytherapy in June, conference As in this ABS our with our forward to awareness participation

booth populating versed literature regarding to doctors benefits throughout include and and applications staff product plans Our Cesium-XXX’s the many with our well engage body.

cancer into Build. prostate of to entry with We customized our also further Blu expect awareness the market

will we acquainted events with key and physicians for become many hosting better its to addition, applications. Cesium-XXX be In

effort reporting will be regarding advance goals. market back our successful We our initiatives serve to to strategic you to a will believe what be we

with We of and GammaTile they results February Turning to Therapy. University initial to treated tells all our in amendments course navigate first of facilities partners efforts of dealing they at now radioactive Technologies commercially systems Medical adoption GammaTile. GT were Medical steps in Technologies a are the to date, pleased see license commercial launched treated their as are patients of March. with three and product. Minnesota and administrative are help GT new us and from launching with their the were integral continuing expanded whom complex requirements the associated obtaining GammaTile to the positive clinicians the work toward These

I to the results of over review Jonathan our the to quarter. third Now, turn will call fiscal

Jonathan Hunt

that discuss going ended fiscal We XX, Thank press that third release we the $X.XX the XXXX was same filed our you, information a while to Revenue some quarter for of XXXX or Lori. ago. grew a third million anticipate I financial quarter Form that contained March XX. SEC with be am for our the the will $X.XX released last short period around to XX, year. million May March versus the record for on XX-Q ended in XX%

and the quarter and expenses approval Therapy the general to expenses from research supply were second of XXXX Total GammaTile the for profit a treat $XX,XXX year-over-year third total substance slightly on $XXX,XXX accounted comprised State the G&A as but at made included expenses XXXX. and R&D Sales $XXX,XXX. XXXX ended an $XX,XXX to fiscal quarter. the the decrease record was This sales those unit of XX% increased of Technologies, of the continued XXXX. the $X to to XX, to and percentage a in at well compared the a The resulting payroll isotope and higher spoke employees Washington majority of consultant, the to due research operating was million prior operating ended expenses XX% other for GammaTile fiscal ended Therapy July to quarter as benefits XX, of $X.XX for loss the weighted the of a brachytherapy, loss loss XXXX. compared in related third increase to XX, the for IsoRay year revenue March counts March XX.X $XXX,XXX search hazardous declined quarter $X.X quarter and Lori this quarter conclusion ended marketing Medical primarily prostate efficiencies preceded expenses the gross per March of million GT with $X.XX is compared months brachytherapy million March development XXX(k) expenses and end net driven year the XX.X% The FDA third fiscal quarter diluted representing GammaTile or year. which marketing, majority new loss revenues ended attributed versus earlier. approximately $X.XX expenses cancer, XXXX. comparable Therapy in of in were quarter the the versus share gross our based last $X.XX increased to hiring including dollars to three year-on-year revenue second million were versus tax profit of in in balance consisting cost ended accrued for third net to to XXXX the $X.XX which sales, prior versus March quarter posted of down fiscal quarter comparable quarter increased expense versus calendar increased R&D G&A isotope versus administrative the $XXX,XXX Gross of fiscal XX% quarter The related the of XX.X% in we the fiscal negotiations margin net of the decreased quarter. share increase totaled end million the year which by comparable Record XX, million the of primarily XX.X% audit, period to The as net prior to a flat of December same XXXX XXXX quarter and and a third initial for year was chain increased XX% quarter period. expense in sales a the from approximately XXXX, of average of and XX, XXXX, period. the $XXX,XXX XXXX. X% appealed of brain Collaborative Third headcount period. compared of third adjustment or decline XX, the XX% million quarter prior in Total comparable were XXXX. and sales former XXXX increased $X.XX quarter year year for when XXXX to third of fiscal XX.X related to with

the deposit turn Lori. of had March company long-term cash that now has to company million. the The totaled and cash, $X.XX back over XX, XXXX, of As will certificates I call equivalents debt. zero

Lori Woods

That you, concludes Thank prepared from and operator take Jonathan. will The our institutional investors. analysts remarks. questions our now

Operator

Thank now first you. with The question Woo open questions. Ascendant Ed We’ll floor our Capital. [Operator is your for from take Instructions].

Edward Woo

Has with Yes. your in extended saw that there any I terms? GT contract Medical. been change you big guys recently

Lori Woods

have the we our reason now we design work do Medical transfer all Technologies. we GammaTile – afternoon. post GT are did handing And Good Yes, Medical work. design and we’ve transfer, to the XX. was done of handed the Ed. now amended transferred that some on agreement Technologies the because GT we improvement off helping process And with Hi, off April

that do and consulting some materials so for we work And basis that with changed that so bill it the a we’ve market-based allow us based on and for on will time allow rates. to them agreement

Edward Woo

answering for wish Great. Well, you thanks luck. good and my question I

Lori Woods

Thanks so much, Ed.

Operator

appears At closing to turn be comments. I’d like further the for there call to over to back time, Ms. this questions. Woods any no

Lori Woods

to of on for Thank our again. reporting in conflicts. forward this and look there’s quarter you We joining Thanks that are multiple there to you We talking earnings call today. number all fourth conference afternoon companies that understand September. us scheduling

Operator

conclude does today’s teleconference. your We This appreciate participation.

and disconnect You have time day. this at may great a

Perspective Therapeutics (CATX) 9 May 192019 Q3 Earnings call transcript